Oncology Intelligence Report 2014 Broucher

Oncology Intelligence Report 2014 Broucher

• 1.
  ONCOLOGY World’s Largest ActiveResource for Decision Making 2014 DRUG REPORT 2237 Active Drugs in Development 931 Active Cancer Drug Developers Profiles 37 Cancer Indications - Pipeline Analysis Largest Coverage with 33 Countries covered Globally Market Size and Forecast on 19+ Cancer Indications 523 Clinical,360 Preclinical & 48 Discovery Companies Profiles Individual Drug Mechanism of Action & DrugTarget First of ItsType - Fine Details Oriented Analysis Packed in1055 Pages Intelligence Report. 2 nd EDITION 228 Emerging Cancer Drug Targets Details 50+ Protein Kinases as Emerging Cancer DrugTargets
• 2.
  FOCUSED DECISION MAKING 931 COMPANIES Worldwide33 Countries Coverage, with Active 931 Drug Developers Profiles. Deals, Funding, Technology Partners with Key Decision Makers e-mail & LinkedIn IDs. 19 Cancer Indications, with In-depth Pipeline Analysis & Market Forecast. 2237 Pipeline Molecules Profiles, Drug Target & Mechanism of Action. ACTIVE 2237 ACTIVE CANCER DRUGS IN DEVELOPMENT 4264 ACTIVE CANCER DRUG INDICATIONS Comprehensive Intelligence - Helps to recreate all missing links in Decision Support. Duplication of Information is avoided to generate Precise & Clear Information. Only Oncology treatment focused Activities and Deals are included. Single Comprehensive Solution greatly reduces time, and keeps Information at Fingertip’s. Much Attractively Priced in compare to peers. First Purchase provides an option to upgrade at 50% Discount on next yearly editions. SAVE TIME & MONEY report highlights COVERAGE FOCUSED DECISION MAKING Single Report provides Answers to Many
• 3.
  MARKET SIZE &FORECAST DISEASE OVERVIEW LARGEST ACTIVE DRUG PIPELINE MONOCLONAL ANTIBODIES STEM CELL THERAPIES VACCINES PHASE III EXPECTED LAUNCHES DRUG TARGETS IN DEVELOPMENT MOST ACTIVE COMPANIES & DRUG PARTNERS DETAILED PIPELINE ANALYSIS INDIVIDUAL INDICATION COVERINGfor TOP SELLING DRUGS & THEIR SALES TREATMENT OPTIONS EPIDEMIOLOGY COMPLETE INSIGHTS INDIVIDUAL DISEASE CATEGORY includeson BREAST CANCER Pipeline Analysis & Market Forecast COLORECTRAL CANCER Pipeline Analysis & Market Forecast PROSTATE CANCER Pipeline Analysis & Market Forecast MELANOMA Pipeline Analysis & Market Forecast OVARIAN CANCER Pipeline Analysis & Market Forecast HEPATOCELLULAR CARCINOMA Pipeline Analysis & Market Forecast MULTIPLE MYELOMA Pipeline Analysis & Market Forecast LEUKEMIA / HEMATOLOGICAL MAGLIANCIES AML/ALL/CML/CLL/Others Pipeline Analysis & Market Forecast NON-HODGKIN LYMPHOMA Pipeline Analysis & Market Forecast GASTRIC CANCER Pipeline Analysis & Market Forecast PANCREATIC CANCER Pipeline Analysis & Market Forecast BRAIN CANCER INCLUDING GLIOBLASTOMA Pipeline Analysis & Market Forecast HEAD & NECK CANCER Pipeline Analysis & Market Forecast BLADDER CANCER Pipeline Analysis & Market Forecast THYROID CANCER Pipeline Analysis & Market Forecast RENAL CELL CARCINOMA Pipeline Analysis & Market Forecast HODGKIN LYMPHOMA Pipeline Analysis & Market Forecast (299 Active Molecules) (248 Molecules) (165 Active Molecules) (265 Active Molecules) (167 Active Molecules) (201 Active Molecules) (166 Active Molecules) (149 Active Molecules) (107 Active Molecules) (80 Active Molecules) (58 Active Molecules) (170 Active Molecules) (18 Active Molecules) (149 Molecules) (67 Active Molecules) (76 Active Molecules) (49 Active Molecules) (24 Active Molecules) SARCOMA Pipeline Analysis & Market Forecast (62 Active Molecules) Other Cancer Indications Drug Development Pipeline Includes - Non-Melanoma Skin Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Endometrial Cancer; Oseophageal Cancer; Billary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Anal Cancer; Gastrointestinal Stromal Tumor; Waldenstrom’s Macroglobulinemia; Anaplastic Astrocytoma; Neuroblastoma; Nasopharynx Cancer; Medulloblastoma; Oral Cancer; Wilm’s Tumor & Rare Oncology/Orphan Indications. LUNG CANCER NSCLC/SCLC Pipeline Analysis & Market Forecast check Table of Contents and Sample Pages, for further Idea on Disease Coverage. Active Drug Pipeline of Major Cancer Indications 37 Development
• 4.
  ONCOLOGY DRUG REPORT 2014World’s LargestActive Resource for Decision Making How Report will Business Development Head Largest Active & Updated Companies List Detailed Profiles to plan Focused Strategies LinkedIn & E-mail IDs of Key Decision Makers Help Drug Developers / Scientists CXOs / VPs / Directors Investors / Analysts 2200+ Drugs Mechanism of Actions Detailed Analysis on 228 Cancer Drug Targets Identify first in class & best in class molecules Bring More Data under Analysis Identify the Net Worth of Investments Forecast the Real Impact of assets acquisition Clinical Directors Complete Active Pipeline Analysis Robust Data, helps in Predicting the Future of Cancer Drug Discovery Visualize all possible Untapped Opportunities Check current Business Partners & Investors Robust Data at Fingertips with validating links Your Drug’s Competitive Position with immense Partnering Opportunities Profiles of Emerging Competitors and their Developmental Strategies Latest Clinical Trial with the “Last Update Status” Identify Clinical Trial Partners & CRO
• 5.
  598 pages contains,523 Active Cancer Clinical Companies’ Profiles. Each page profile is written in a mini report format and covers company’s complete active clinical, pre- clinical & discovery drug pipeline for various cancer indications, individual drug name(s), targets, mecha- nism of action, first in class, SPA / fast track & orphan drug (FDA/EMEA) status; clinical trials latest update status, with links for all active cancer indications to external authentic web source to validate information. Also contains technological collaborations, drug discov- ery / development proprietary platform, key investors, oncology focused partnering deals & agree- ments. Details of key management/ deci- sion makers, their LinkedIn and email IDs; employee numbers; assets valuation, market cap with ticker no. etc. 215 pages contains, 360 Active Cancer Pre-clinical stage companies’ Profiles. Each company profile contains short description on proprietary drug discovery / development platforms, technological collabora- tions, partners, key investors and oncology focused major part- nering deals & agreements. Alsoincludes,cancerfocusedactivepreclinicalanddiscoverystage pipeline with drug targets and their mechanism of drug action. Key contacts, year of incorporation, assets valuation, employ- ee range, market cap with stock exchange/ticker number, names of key management/decision makers. It pro- vides an immense partnering opportunities in the early drug devel- opment stage. Section - A Section - D Section - E Section - F Section - B Section - C 6 pages Infographics Distributes Active 931 cancer drug develop- ing companies among their Geographic Region, year of In- corporation and total employee size. All together is to identify the complete landscape of current and emerging cancer innovation clusters. 28 pages contains, 48 Active Discovery stage companies profiles. Their proprietary technology platforms, partners, key investors and oncology focused major partnering deals & agreements. Active discovery stage pipeline with drug targets and their mechanism of drug action is also included. 95Pages details , Tables and Featured boxes contain- ing complete updates on clinical developmental profiles of 19 major cancer indications including Lung, Breast, Colorectal, Melanoma, Prostrate, Ovarian, Pancreatic, HCC, Gastric, Multiple Myeloma, Leukemia, NHL, Hodgkin Lymphoma, Brain, Head and Neck, RCC, Bladder, Thyroid and Sarcoma. Each profile contains epidemiology, market forecast, top selling chemotherapies & targeted therapies, PhIII pipeline drugs with their clinical trial design & combination drugs, key partners with expected launch. Also contains monoclonal antibodies, vac- cine and biologics in development; complete PH II & PH I pipeline with partners. Top 10 vs. other developer’s strategies, total kinases in development for particular indication. Identify 2012 major drug advances, failures and new entrants. 63 pages Infographics and Tables are designed to provide the complete insights on 2237 active molecules, present in various developmental stages for cancer treatment. Descriptive Tables outlines various Monoclonal Antibodies, Antibody Drug Conjugates, Cancer Vaccines, recombinant & syn- thetic proteins, gene & Virus based therapies, stem cell and other cell based therapies descriptions under clinical & preclinical studies. Section B also includes 228 Cancer Drug Targets complete coverage along with drugs under development for each target. This helps in clear identification of emerging cancer targets and helps in predicting future of cancer drug development. Special section for Protein Kinas- es is designed to identify its established and emerging roles. Also Top 10 companies target selection strategies can be easily de-marked. Tables also includes Top 20 companies details in terms of numbers of molecules in development. ONCOLOGY DRUG REPORT 2014World’s Largest Active Resource for Decision Making Report Architecture Highly Inter-Linked 1055 Pages Intelligence Report divided into 6 Sections
• 6.
  ONCOLOGY DRUG REPORT 2014World’s LargestActive Resource for Decision Making Info graphics/ Tables / Figures / Featured Boxes Interactive Colourful Design (Easy to read) Yearly 523! 408!  2237 Active Cancer Treatment Drugs   Yes (69 active molecules for rare diseases)  37 (Cancer Indications Pipeline Analysis)    1092 (Active Preclinical & Discovery molecules)   Worldwide (33 Countries)   Bring More Active Data under Analysis OncologyDrugReport 2014 OncologyDrugReport 2014 OtherDatabasesOtherDatabasesOtherReportsOtherReports Figures & Tables (usually) Simple Designs at release time only 125-180 Clinical Companies Usually discovery data is not the part of reports  300-350 Non Treatment are Included  Limited Yes (Limited Information) May Present Multiple Indications Reports Usually Ph III and Ph II   100-150 molecules  Depends on Report type US and Europe   Market Forecast with the help of available data Figures & Tables (usually) Interactive Complex Design Regularly Large Number with non-active Status Updates on Preclinical Companies are missing  Large Number with mixed and non-active Info  Limited Yes (Limited with noupdates) May Present More Emphasis on Main Indications    200-250 molecules   US and Europe   Bring more disease areas on the same platform Layout Design Updates Companies Coverage (Clinical) Companies Coverage (Exclusive Preclinical & Discovery) Platform Technologies Details Drugs in Development Individual Drug’s Mechanism of Actions First In Class Details Orphan Drug Indications 228 Drug Targets Details Total Cancer Indications coverage in single report DETAILED PIPELINE (Clinical, Pre-Clinical & Discovery) Individual Drug’s Active Clinical Trials info with update status Top 10 Companies Drug Development Strategies Preclinical & Discovery Stage Coverage Market Size and Forecast of Individual Indications Oncology Focused Deals (with size and details) Country Coverage LinkedIn & Email Ids Full References for the validation of Data Major Emphasis approx 4500 USD approx 20000 USD Annual subscriptionPrice in USD *     Oncology Drug Report’s First Edition was published in March 2013, and subsequently new updated editions shall be added every year. The buyers are eligible for 50% discount on Cover price on all upcoming editions (March 2015 onwards) to upgrade intelligence. For any further details kindly mail us at [email protected] !    ! Non Active clinical/pre-clinical trials molecules or companies are not considered. Also only Oncology treatment molecules/companies are profiled. No disease care/ management, diagnostic molecules are counted/profiled. $ 3490 USD In compare to others
• 7.
  your skilled expertin data suppot We are a group of highly innovative professionals, working together to provide the real insights on massive growing biological data. In last few years, we have developed our proprietary pharma intelligence database with over 14,400+ active companies records, and our core focus is to identify & map technology competitiveness of this daily growing list. Thanks to our 35,000+ Top Management connections on LinkedIn, which helps us with a constant knowledge sharing on their companies, whenever required. Worldwide coverage on active companies to bring more data under analysis and to provide a complete landscape on drug development. METHEDOLOGY To present with a comprehensive story we closely monitor all year round activities and follows events, press releases, social media etc., for routine updates. Also, we subscribes to a large number of extensive & authentic resources to feed our in- ternal Knowledgebase, which together with our primary research & personal interviews enables us to develop a quality and accurate intelligence, in form of Comprehensive Reports. All Individual Companies Profiles, covered in single Report, to cross-check the intelligence generated in the report, with neumrous links to justify all information. LinkedIn & E-mail IDs of all Key Decision Maker(s), to identify and link with focused exec- utives for partenering & business development opportunities. few Report Buyers include Unique features of Comprehensive Series Other Reports in Comprehensive Series are:- Neurology Drug Report 2014 - FIRST EDITION Infectious Disease Drug Report 2014 - FIRST EDITION